In the absence of an approved product, investors’ focus will be on the progress of Zynerba Pharmaceuticals, Inc.’s ZYNE lead pipeline candidate when the company reports first-quarter 2019 results.
The company’s earnings beat the Zacks Consensus Estimate in two of the last four quarters and missed the same twice with the average positive surprise being 2.11%.
Shares of Zynerba have surged 289.2% so far this year compared with the industry‘s rise of 6.6%.
In the last reported quarter, Zynerba reported a positive earnings surprise of 34.33%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
Investors will likely focus on the progress of the company’s lead pipeline candidate, Zygel, on the first-quarter earnings call.
Zynerba is developing Zygel multiple neuropsychiatric indications including Fragile X syndrome (“FXS”), and developmental and epileptic encephalopathies.
In March, the company initiated a phase II study to evaluate Zygel in autism spectrum disorder in pediatric patients.
Meanwhile, the company is looking to get an approval for Zygel for treating FXS. A pivotal study is evaluating the candidate for treating patients with FXS aged 3 to 17 years. Previously presented data from the study showed improvement in core emotional and behavioral symptoms of statistical significance. Zynerba expects to report top-line data in the second half of this year and submit a new drug application next year.
These developments are likely to drive operating expenses higher in the soon-to-be reported quarter. The company has enough cash to fund its operations beyond 2020.
Zynerba is focused on developing cannabinoid therapies for rare neuropsychiatric disorders.
Our proven model does not conclusively show that Zynerba is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Zynerba’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 46 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Zynerba’s Zacks Rank #2 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Zynerba Pharmaceuticals, Inc. Price and Consensus
Zynerba Pharmaceuticals, Inc. Price and Consensus | Zynerba Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are some stocks from the pharma sector that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Gilead Sciences, Inc. GILD has an Earnings ESP of +1.54% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon Pharma HZNP has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8.
Corbus Pharmaceuticals Holdings, Inc. CRBP has an Earnings ESP of +255.56% and a Zacks Rank #3.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Horizon Pharma Public Limited Company (HZNP) : Free Stock Analysis Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP) : Free Stock Analysis Report
Zynerba Pharmaceuticals, Inc. (ZYNE) : Free Stock Analysis Report
To read this article on Zacks.com click here.